[Treatment of condylomata acuminata with systemically administered recombinant gamma interferon].
29 patients suffering from condylomata acuminata were systemically treated with human gamma-interferon obtained by means of gene technology. The daily dose, subcutaneous applied, amounted to 100 or 200 micrograms. 12 patients were completely cleared by surgical excision and additionally treated with gamma-interferon for 7 days. 3 of them developed recurrences. 17 patients were exclusively treated with gamma-interferon 100 or 200 micrograms daily; they underwent 6 courses of therapy, each lasting 7 days, with interruptions of 3-5 weeks of observation. As a result, 5 patients showed complete remission; 2 patients partially responded. The tolerance of the drug depended on the dose. We did not observe any toxic side effects. Our findings suggest that gamma-interferon subcutaneously given may be effective with genital warts.
D000328:Adult; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000188:drug therapy / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000628:therapy*; D005834:Genital Neoplasms, Male / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000008:administration & dosage*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage*
D011994:Recombinant Proteins; D007371:Interferon-gamma
Behandlung von Condylomata acuminata mit systemisch appliziertem rekombinanten Interferon-gamma.